President Phelps recently earmarked funds to support 2 new internal grant opportunities this fiscal year.
Look for a forthcoming announcement from Gaylah Sublette, MBA, vice president for research and sponsored programs. Applications will be due in November 2020. Grants will be awarded via a competitive review process.
NIH Parent Announcements are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications for specific activity codes, using standard deadline cycles offered 3 times per year.
Parent R03: NIH Small Research Grant Program (Clinical Trial Not Allowed PA-20-200)
The Parent R03 supports discrete, well-defined research projects that can be completed in 2 years and require limited funding ($100,000 direct costs). Different types of projects are supported, including pilot and feasibility studies; secondary analyses of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Because the project is limited, an R03 grant application need not contain extensive detail or discussion. Accordingly, reviewers are directed to evaluate the project's conceptual framework and general approach to the research problem. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or from investigator-generated data. Preliminary data are not required, particularly in applications proposing pilot or feasibility studies.
Interested faculty are encouraged to identify an NIH Institute/Center (IC) that supports their area of research via the R03 IC-Specific Scientific Interests and Contact website and the appropriate Scientific/Research staff to contact regarding their interest in supporting the proposed project. ATSU Sponsored Programs (email@example.com) is available to assist upon request.
The Parent R21 supports research projects in the early and conceptual stages that can be completed in 2 years. R21 studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. A R21 application need not have extensive background material or preliminary information. Accordingly, reviewers will emphasize the conceptual framework, level of innovation, and potential to significantly advance knowledge or understanding. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or, when available, from investigator-generated data. Preliminary data are not required but are strongly encouraged where feasible.
Faculty are encouraged to carefully note which ICs participate in the program announcement of interest and view the ICs' respective areas of research interest at the appropriate R21 IC-Specific Scientific Interests and Contact website. ATSU Sponsored Programs (firstname.lastname@example.org) is available to assist upon request.
The LRPs were established by Congress to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers. The escalating costs of advanced education and training in medicine and clinical specialties are forcing some scientists to abandon research for higher-paying private industry or practice careers. The LRPs counteract the financial pressure by repaying up to $50,000 annually of a researcher's qualified educational debt in return for a 2-year commitment to engage in NIH mission-relevant research.
The application cycle closes on November 20, 2020. Please see www.lrp.nih.gov to learn more about eligibility requirements and benefits of the program.